For reprint rights or to purchase a copy of your Daily Journal photo, email Jeremy_Ellis@dailyjournal.com for prices or call 213-229-5424.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Mergers & Acquisitions

Jul. 2, 2010

Firms Advise on Pharma Merger

Biopharmaceutical company Celgene Corp. acquired Abraxis BioScience Inc. in a $2.9 billion deal approved by both companies' boards of directors.

By Kari Hamanaka

Daily Journal Staff Writer

Biopharmaceutical company Celgene Corp. acquired Abraxis BioScience Inc. in a $2.9 billion deal approved by both companies' boards of directors. The sale was announced Wednesday and is expected to close in the fourth quarter pending stockholder approval.

Abraxis is the developer of Abraxane, a U.S. Food and Drug Administration-approved chemotherapy drug treatment used in metastat...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.